Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Zacks News
Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
by Zacks Equity Research
Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.
Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Exelixis (EXEL) closed at $23.04 in the latest trading session, marking a -0.39% move from the prior day.
New Strong Sell Stocks for February 15th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Implied Volatility Surging for Exelixis (EXEL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately.
Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the fourth quarter on strong sales of Cabometyx.
Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 48.00% and 16.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Exelixis (EXEL) closed at $22.60, marking a -0.96% move from the previous day.
Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
by Zacks Equity Research
Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.
New Strong Buy Stocks for January 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
by Zacks Equity Research
Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.
5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
by Zacks Equity Research
Exelixis (EXEL) lead drug, Cabometyx continues to perform well.
Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Exelixis (EXEL) closed at $23.76, marking a -1.29% move from the previous day.
Is Exelixis (EXEL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (EXEL) Outperforming Other Medical Stocks This Year?
Top 10 Stocks Under $20
by Ryan McQueeney
Today we've highlighted ten stocks that are currently trading for under $20 per share. These stocks currently have seen positive earnings estimate revisions, and a variety of other factors make these companies stand out as having strong upside potential.
Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure
by Zacks Equity Research
Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.
5 Excellent GARP Picks With Cheap PEG Ratio
by Zacks Equity Research
Although PEG ratio is categorized under value investing, this strategy follows the principles of both growth and value investing.
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
by Kinjel Shah
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate
by Zacks Equity Research
A low key week for the biotech sector with focus on regular pipeline updates.
Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.
Why Exelixis (EXEL) Could Be Positioned for a Surge
by Zacks Equity Research
Exelixis (EXEL) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Why Is Exelixis (EXEL) Up 35.9% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss
by Zacks Equity Research
Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.